Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | ESR1 | P03372 | 2/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.39 |
| ▸ | HTR2A | P28223 | 4/20 | 0.39 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HRH1 | P35367 | 2/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | HTR6 | P50406 | 1/20 | 0.32 |
| ▸ | KIF11 | P52732 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20705055 | 0.89 | TDP1 (0.52) | TDP1CYP3A4ESR1ESR2TAAR1 | |
| 1,2-Dibromoethane SCHEMBL28837174 | 0.87 | TDP1 (0.71) | TDP1CYP3A4ESR1ESR2SMN1; SMN2 | |
| SCHEMBL14992059 | 0.85 | CYP3A4 (0.48) | TDP1CYP3A4ESR1ESR2HTR2A | |
| SCHEMBL17501902 | 0.85 | CYP3A4 (0.48) | TDP1CYP3A4ESR1ESR2HTR2A | |
| SCHEMBL18729718 | 0.85 | CYP3A4 (0.48) | TDP1CYP3A4ESR1ESR2HTR2A | |
| Dibromomethane SCHEMBL7950072 | 0.84 | TDP1 (0.75) | TDP1CYP3A4ESR1ESR2SMN1; SMN2 | |
| Dibromomethane SCHEMBL5329477 | 0.84 | TDP1 (0.75) | TDP1CYP3A4ESR1ESR2SMN1; SMN2 | |
| SCHEMBL319391 | 0.82 | TDP1 (0.63) | TDP1CYP3A4ESR1ESR2KDM4E | |
| SCHEMBL5453551 | 0.82 | TDP1 (0.63) | TDP1CYP3A4ESR1ESR2KDM4E | |
| N-Propyl Bromide SCHEMBL1400032 | 0.80 | TDP1 (0.60) | TDP1CYP3A4ESR1ESR2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116234800-A | Copper complexes for the treatment of neurodegenerative disorders | ALS治疗发展学会 | 2023-06-06 | — | — | CN | disclosed |
| CN-115006527-B | Mitochondrion targeting photosensitizer and preparation method and application thereof | 苏州大学 | 2023-03-17 | — | — | CN | disclosed |
| CN-115006527-A | Mitochondrion targeting photosensitizer and preparation method and application thereof | 苏州大学 | 2022-09-06 | — | — | CN | disclosed |
| US-11274114-B2 | Modified mito-metformin compounds and methods of synthesis and use thereof | THE MEDICAL COLLEGE OF WISCONSIN, INC. (US) | 2022-03-15 | — | — | US | disclosed |
| US-10576093-B2 | Neuroprotection by mitochondria-targeted metformin | IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2020-03-03 | — | — | US | disclosed |
| EP-3558282-A1 | SYNERGISTIC INIHIBITION OF TUMOR CELL PROLIFERATION INDUCED BY COMBINED TREATMENT OF METFORMIN COMPOUNDS AND IRON CHELATORS | The Medical College of Wisconsin, Inc. (US) | 2019-10-30 | — | — | EP | disclosed |
| EP-3179994-B1 | MODIFIED MITO-METFORMIN COMPOUNDS AND METHODS OF SYNTHESIS AND USE THEREOF | MEDICAL COLLEGE WISCONSIN INC (US) | 2019-04-24 | — | — | EP | disclosed |
| US-20190091245-A1 | Neuroprotection by mitochondria-targeted metformin | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-03-28 | — | — | US | disclosed |
| WO-2018119207-A1 | SYNERGISTIC INIHIBITION OF TUMOR CELL PROLIFERATION INDUCED BY COMBINED TREATMENT OF METFORMIN COMPOUNDS AND IRON CHELATORS | THE MEDICAL COLLEGE OF WISCONSIN, INC. (US) | 2018-06-28 | — | — | WO | disclosed |
| US-9956233-B2 | Neuroprotection by mitochondria-targeted metformin | IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2018-05-01 | — | — | US | disclosed |
| US-20170275313-A1 | MODIFIED MITO-METFORMIN COMPOUNDS AND METHODS OF SYNTHESIS AND USE THEREOF | THE MEDICAL COLLEGE OF WISCONSIN, INC. | 2017-09-28 | — | — | US | disclosed |
| EP-3179994-A1 | MODIFIED MITO-METFORMIN COMPOUNDS AND METHODS OF SYNTHESIS AND USE THEREOF | The Medical College of Wisconsin, Inc. (US) | 2017-06-21 | — | — | EP | disclosed |
| EP-2424872-B1 | NEUROPROTECTIVE COMPOUNDS AND THEIR USE | MEDICAL COLLEGE OF WISCONSIN INC (US) | 2017-05-17 | — | — | EP | disclosed |
| US-20170106006-A1 | Neuroprotection by Mitochondria-Targeted Metformin | AIX-MARSEILLE UNIVERSITE (FR) | 2017-04-20 | — | — | US | disclosed |
| WO-2016025725-A1 | MODIFIED MITO-METFORMIN COMPOUNDS AND METHODS OF SYNTHESIS AND USE THEREOF | THE MEDICAL COLLEGE OF WISCONSIN, INC. (US) | 2016-02-18 | — | — | WO | disclosed |
| US-8962600-B2 | Neuroprotective compounds and their use | THE MEDICAL COLLEGE OF WISCONSIN, INC. (US) | 2015-02-24 | — | — | US | disclosed |
| US-20120108549-A1 | NEUROPROTECTIVE COMPOUNDS AND THEIR USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-05-03 | — | — | US | disclosed |
| EP-2424872-A1 | NEUROPROTECTIVE COMPOUNDS AND THEIR USE | The MCW Research Foundation, Inc. (US) | 2012-03-07 | — | — | EP | disclosed |
| WO-2010126719-A1 | NEUROPROTECTIVE COMPOUNDS AND THEIR USE | MCW RESEARCH FOUNDATION, INC. (US) | 2010-11-04 | — | — | WO | disclosed |
| US-20090281330-A1 | Nitrons Carrying a Positive Charge and Usable in Trapping Free Radicals, Especially the Superoxide Radical | TORDO PAUL | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11274114-B2 | Modified mito-metformin compounds and methods of synthesis and use thereof | TFAM, MFN2, MT-ND5 | TDP1 1595/4885CYP3A4 345/4885ESR1 2956/4885 |
| US-20170275313-A1 | MODIFIED MITO-METFORMIN COMPOUNDS AND METHODS OF SYNTHESIS AND USE THEREOF | TFAM, MFN2, MT-ND5 | TDP1 1595/4885CYP3A4 345/4885ESR1 2956/4885 |
| US-20090281330-A1 | Nitrons Carrying a Positive Charge and Usable in Trapping Free Radicals, Especially the Superoxide Radical | SOD1, TXN2, NOX1 | TDP1 1248/4885CYP3A4 1055/4885ESR1 698/4885 |
| US-20170106006-A1 | Neuroprotection by Mitochondria-Targeted Metformin | NLN, MFN2, TFAM | TDP1 506/4885CYP3A4 3967/4885ESR1 4405/4885 |
| US-10576093-B2 | Neuroprotection by mitochondria-targeted metformin | NLN, MFN2, TFAM | TDP1 506/4885CYP3A4 3967/4885ESR1 4405/4885 |
| US-20120108549-A1 | NEUROPROTECTIVE COMPOUNDS AND THEIR USE | NLN, ATP6V1B2, BDNF | TDP1 592/4885CYP3A4 2747/4885ESR1 4351/4885 |
| US-20190091245-A1 | Neuroprotection by mitochondria-targeted metformin | NLN, MFN2, TFAM | TDP1 506/4885CYP3A4 3967/4885ESR1 4405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.